Bibliography
- VANE JR: Overview. In: Selective COX-2 Inhibitors: Pharma-cology, Clinical Effects and Therapeutic Potential. Kluwer Academic Publishers, London (1997). In Press.
- VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature (1971) 231:232–235.
- FU JY, MASFERRER JL, SIEBERT K, RAZ A, NEEDLEMAN P: The induction and suppression of prostaglandin Hz synthase (cyclooxygenase) in human monocytes. Biol. Chem. (1990) 265:16737–16740.
- XIE W, CHIPMAN JG, ROBERTSON DL, ERIKSON RL, SIM-MONS DL: Expression of a mitogen-responsive gene encoding pr ostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA (1991) 88:1692–1696.
- BROWNER MF: COX-2: a structure-based approach to drug discovery. In: Selective COX-2 Inhibitors: Pharmacol-ogy, Clinical Effects and Therapeutic Potential. Kluwer Aca-demic Publishers, London (1997). In Press.
- LUONG C, MILLER A, BARNETT J et al.: Flexibility of the NSAID binding site in the structure of human cyclooxy-genase-2. Nature Structure Biol. (1996) 3:927–933.
- PICOT D, LOLL PJ, GARAVITO RM: The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature (1994) 367:243–249.
- PAIRET M: Differential inhibition of COX-1/COX-2 by NSAIDs. In: Selective COX-2 Inhibitors: Pharmacology, Clini-cal Effects and Therapeutic Potential Kluwer Academic Publishers, London (1997). In Press.
- FENNER H: New classification of aspirin-like drugs. In:Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. Kluwer Academic Publishers, London (1997). In Press.
- SIMMONS D: COX-2 and apoptosis: NSAIDs as effectorsof programmed cell death. In: Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. Kluwer Academic Publishers, London (1997). In Press.
- DUBOIS R, SHAO JY, SHENG H, WILLIAMS C, BEAUCHAMP D: Selective inhibition of intestinal tumorigenesis via selective inhibition of COX-2. In: Selective COX-2 Inhibi-tors: Pharmacology, Clinical Effects and Therapeutic Poten-tial. Kluwer Academic Publishers, London (1997). In Press.
- BAZAN N, MARCHESELLI V, MUKHERJEE P et al: COX-2 in the brain and retina: role in neurone survival. In: Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. Kluwer Academic Publishers, London (1997). In Press.
- PATRONO C: Cyclooxygenase enzymes in human vas-cular disease. In: Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. Kluwer Academic Publishers, London (1997). In Press.
- GARCIA RODRIGUEZ LA: Epidemiology of the relative safety of NSAIDs. In: Selective COX-2 Inhibitors: Pharma-cology, Clinical Effects and Therapeutic Potential. Kluwer Academic Publishers, London (1997). In Press.
- HAWKEY C: Gastrointestinal effects of NSAIDs. In: Selec-tive COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. Kluwer Academic Publishers, London (1997). In Press.
- FROLICH J: Avoidance of renal side-effects of NSAIDs. In: Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. Kluwer Academic Publishers, London (1997). In Press.
- GRYGLEWSKI R: Aspirin induced asthma (MA) and cy-clooxygenase. In: Selective COX-2 Inhibitors: Pharmacol-ogy, Clinical Effects and Therapeutic Potential. Kluwer Academic Publishers, London (1997). In Press.
- FURST D: Meloxicam: clinical experience with an NSAID with relative COX-2 selectivity. In: Selective COX-2 Inhibi-tors: Pharmacology, Clinical Effects and Therapeutic Poten-tial. Kluwer Academic Publishers, London (1997). In Press.
- FORD-HUTCHINSON A: New highly selective COX-2 in-hibitors. In: Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. Kluwer Academic Publishers, London (1997). In Press.
- NEEDLEMAN P: Development of novel COX-2 inhibitors. In: Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. Kluwer Academic Publishers, London (1997). In Press.